An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl

Journal of Cardiovascular Pharmacology

Volumn 23, Issue , 1994, Pages S44-S47

  Moody, A P ^a   Al Khaffaf, H S ^b   Lehert, P ^c   Harris, P L ^a   Charlesworth, D ^b  

^a Broad Green Hospital   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c Univ de l'Etat Mons   (Belgium)

Author keywords

Intention to treat; intermittent claudication; Naftidrofuryl; Peripheral arterial disease; Risk factors; Tread mill

Indexed keywords

NAFTIDROFURYL; SEROTONIN;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTERMITTENT CLAUDICATION; LEG ISCHEMIA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; WALKING;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; NAFRONYL; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; WALKING;

EID: 0028281063     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199406030-00009     Document Type: Article

References (11)

1. Bloor K. Natural history of arteriosclerosis of the lower extremities. Ann R Coll Surg Eng 1961;28:36-52.
2. Boobis LH, Bell PRF. Can drugs help patients with lower limb ischaemia? Br J Surg 1982;69(suppl):17-23.
3. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: Outcome and risk factors. BMJ 1986;293:1137-40.
4. Bevan EG. Waller PC, Ramsey LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs Ageing 1992;2:125-36.
5. Maloteaux JM, Haiech J, De Campaneere D, Berta P, Vidal N. Biochemical and physiological evidences for anti-serotonergic properties of naftidrofuryl. Arzneimittelforschung 1986;36:1194-8.
6. Elert C, Niebel W, Karuse E, Satler P. The effect of naftidrofuryl on energy metabolism in the musculature of limbs with impaired blood flow. Therapiewoche 1976;23:3947-50.
7. Adhoute G, Bacourt F. Barrai M, et al. Naftidrofuryl in chronic arterial disease. Results of six month controlled multicentre study using naftidrofuryl tablets 200 mg. Angiology 1986;37:160-7.
8. Adhoute G, Andreassian B, Boccalon H. et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl, results after 6 months of a controlled multicentre study. J Cardiovasc Pharmacol 1990;16(3):75-80.
9. Triibestein G. Böhme H, Heidrich H. et al. Naftidrofuryl bei arterieller Verschlusskrankheit. Dtsch Med Wochenschr 1984;109:745-50.
10. Kriessmann A, Neiss A. Klinischer Wirksamkeitsnachweis von naftidrofuryl bei Claudicatio intermittens. Vasa 1988:17(suppl 24):27-32.
11. Gillings D. Koch G. The application of the principle of in-tention-to-treat to the analysis of clinical trials. Drug Information J 1991;25:411-24.